· The option exercise grants IOVaxis an exclusive license to develop and
commercialize mutant RAS vaccines TG01/TG02 in Greater China and Singapore
  · IOVaxis will make an immediate down payment of USD 300.000 on the agreed
option exercise fee of USD 3.000.000
  · Circio has granted IOVaxis a six-month payment extension on the remainder of
the option exercise fee
  · IOVaxis intends to initiate its first TG01 clinical trial in pancreatic
cancer during 2024

Oslo, Norway 19 March 2024 - Circio Holding ASA (OSE: CRNA) announces that
following approval of the investigational new drug (IND) application by the
Chinese National Medical Products Administration (NMPA) on 1 March 2024, IOVaxis
Therapeutics of Nantong, China, has on 15 March 2024 exercised its option to
license mutant RAS cancer vaccines TG01 and TG02. The license grants IOVaxis
exclusive rights to develop and commercialize the TG vaccines in Greater China
and Singapore.

Under the license agreement between the parties, Circio is entitled to receive a
milestone payment of USD 3m following the exercise of the license option. The
total deal includes up to USD 10m in clinical development milestones, as well as
royalties and commercial milestones on future sales.

Due to an ongoing process by IOVaxis to secure capital to cover both the
milestone payments and the planned phase 1/2 TG01 clinical program and a re
-evaluation around the TG01 intellectual property and data protection rights in
China, IOVaxis has requested a six-month payment extension of the option fee and
a discussion around certain commercial terms. The parties have agreed that
IOVaxis will pay USD 300.000 of the option fee to Circio immediately, and that
the remaining balance will be due on 15 September 2024. If the payments are not
made by the agreed dates, the exclusive license will expire on 15 September
2024.

Dr. John Wang, CEO of IOVaxis Therapeutics, said: "Our substantially expanded
IND-package has now been approved by the NMPA, and we are very eager to bring
TG01 into the clinic as rapidly as possible to provide a much-needed targeted
therapeutic option to patients in China with RAS-mutated pancreatic cancer. The
IND-approval was also a critical milestone for our ongoing investor dialogues to
secure the required capital for the planned TG01 development program in China
and Singapore, and we are very grateful for the flexibility shown by the Circio
team to grant an extension to allow further discussions between the parties and
with our investors to take place".

Dr. Erik Digman Wiklund, CEO of Circio Holding ASA, added: "The partnership with
IOVaxis is an important component of our aim to bring TG01 development forward
through strategic collaborations in multiple settings and geographies. Dr. Wang
and his team have shown strong commitment to get the IND approved, which
required a substantial investment of time and resources by IOVaxis to develop a
broad additional pre-clinical data package. We are very pleased to have such a
dedicated partner and expect that the IND approval will make their fundraising
successful. We look forward to taking our partnership to the next stage and
initiate clinical development in China, which will be the first time TG01 is
tested in an Asian patient population".

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for rare disease, vaccines, and cancer. The proprietary
circVec technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA from DNA and viral vectors, which can be
deployed for many purposes. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation, and is subject to disclosure requirements pursuant to
Section 5-12 of the Norwegian Securities Trading Act. The stock exchange
announcement was published by Renate Birkeli, Investor Relations, Circio Holding
ASA.